For many clinical research teams, AI adoption has started informally. Public AI tools are used for drafting, summarization, protocol review, meeting preparation, signal review, coding support, and operational decision-making. In many organizations, this use developed faster than internal governance, oversight, and training approaches.
Regulators are now making it increasingly clear that AI does not operate outside existing GCP and computerized system expectations.
The EMA Guideline on Computerised Systems and Electronic Data in Clinical Trials explicitly places Artificial Intelligence (AI) within the computerized systems landscape used in clinical research. The same guidance also reinforces expectations around user responsibilities, training, oversight, validation, and controlled use of computerized systems within clinical trials.
At the same time, the EU AI Act introduces explicit AI literacy obligations for organizations deploying AI systems.
Together, these developments create a new operational reality for sponsors, CROs, and service providers:
For clinical trial organizations, the lesson is clear. AI may support drafting, review, summarization, or analysis. It does not carry regulatory responsibility. Qualified humans remain accountable for the decisions, documentation, and rationale.
AI is increasingly used to support protocol review, risk assessment preparation, oversight summaries, and operational communication.
AI-supported workflows can influence signal interpretation, prioritization, and review decisions.
Inspection readiness increasingly depends on demonstrating governance around computerized systems, data integrity, and decision accountability.
| Regulatory Area | Key Source | Why It Matters |
|---|---|---|
| GCP | ICH E6(R3) | Requires qualified personnel, oversight, and controlled computerized systems. |
| Computerized Systems | EMA Computerised Systems Guideline | Explicitly includes AI within the computerized systems landscape. |
| AI Literacy | EU AI Act Article 4 | Introduces organizational expectations around AI literacy. |
| Data Integrity | MHRA GxP Data Integrity Guidance | Reinforces traceability, reviewability, and controlled processes. |
| Privacy & Security | GDPR / HIPAA | Restricts inappropriate use of sensitive or personal data in AI tools. |
| AI Governance | FDA/MHRA/Health Canada GMLP | Reinforces validation, transparency, and human oversight expectations. |
Informal AI use across teams
AI use often begins without formal governance or documented expectations.
Unclear accountability
Teams may assume AI-generated outputs are inherently reliable or compliant.
Limited understanding of computerized system expectations
Many users do not connect AI use with validation, oversight, or data integrity obligations.
Inspection-readiness concerns
Sponsors and CROs increasingly need to explain how AI-supported activities remain controlled and reviewable.
Recent FDA warning letters are reinforcing clear expectations around AI oversight. Learn more…
No structured capability development
Organizations frequently establish governance documents before building practical user understanding.
Capability development should be proportionate to actual workflow use.
For clinical trial organizations, that usually includes:
This does not require every employee to become an AI expert.
It does require organizations to ensure personnel understand how AI-supported activities fit within existing GCP, computerized systems, and data integrity expectations.
AI use in clinical trials is increasingly moving into regulated operational territory.
Organizations do not need to stop innovation. They do need teams that understand how AI use fits within GCP, computerized systems, data integrity, and accountability expectations.
That capability is quickly becoming part of operational readiness.
MyRBQM® Academy’s AI Essentials for Clinical Trials (GCP-Compliant) certification helps clinical teams understand how AI can be used responsibly in GCP-regulated environments.
The 70-min, self-paced e-course is designed for professionals in Clinical Operations, QA, Data, Central Monitoring, Medical Monitoring, and study leadership who need a practical baseline before AI use becomes broader, faster, or harder to control.
Need a quote, speaker, or more info about Cyntegrity? Reach out directly to our media contact for timely assistance.
Industry Solutions
Featured Insights
Start Your Roll-Out
RBQM Capability Pathway
Quick Answers
